Curcumin ameliorates dextran sulfate sodium-induced experimental colitis by blocking STAT3 signaling pathway

International Immunopharmacology

Volumn 17, Issue 2, 2013, Pages 314-320

  Liu, Liu ^a   Liu, Yu Lan ^a   Liu, Gong Xiang ^a   Chen, Xi ^a   Yang, Kun ^a   Yang, Yun Xue ^a   Xie, Qin ^a   Gan, Hua Kui ^b   Huang, Xiao Li ^a   Gan, Hua Tian ^a  

^a SICHUAN UNIVERSITY   (China)

^b The First People's Hospital of Neijiang City   (China)

Author keywords

Curcumin; Dextran sulfate sodium induced colitis; Signal transducer and activator of transcription 3 (STAT3); Ulcerative colitis

Indexed keywords

CURCUMIN; DEXTRAN SULFATE; DIMER; INTERLEUKIN 1BETA; MYELOPEROXIDASE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DNA BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPRESSION; GEL MOBILITY SHIFT ASSAY; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THERAPY EFFECT; ULCERATIVE COLITIS; WESTERN BLOTTING;

CURCUMIN; DEXTRAN SULFATE SODIUM-INDUCED COLITIS; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3); ULCERATIVE COLITIS;

ANIMALS; COLITIS; COLON; CURCUMIN; DEXTRAN SULFATE; DOWN-REGULATION; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED BALB C; PEROXIDASE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881499669     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.06.020     Document Type: Article

References (40)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29. (Pubitemid 34851835)
2. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000;118: S68-82. (Pubitemid 30094436)
3. Katz JA. Advances in the medical therapy of inflammatory bowel disease. Curr Opin Gastroenterol 2002;18:435-40. (Pubitemid 34665102)
4. Reddy JG, Loftus Jr EV. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 2006;35:837-55. (Pubitemid 44802970)
5. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000;51:289-98. (Pubitemid 30216038)
6. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998;22:382-9. (Pubitemid 28113526)
7. Stevens C,Walz G, SingaramC, LipmanML, Zanker B,Muggia A, et al. Tumor necrosis factor-a, interleukin-1, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992;37:818-26.
8. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293-322. (Pubitemid 28183367)
9. Mudter J,Weigmann B, Bartsch B, Kiesslich R, Strand D, Galle PR, et al. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am J Gastroenterol 2005;100:64-72. (Pubitemid 41623270)
10. Musso A, Dentelli P, Carlino A, Chiusa L, Repici A, SturmA, et al. Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. InfammBowel Dis 2005;11: 91-8. (Pubitemid 40711212)
11. Ali RAR, Hartnett L, Lee JM. The level of serum cytokines, chemokines and the colonic STAT3 activation pattern in IBDpatients are influenced by disease activity and duration. Gastroenterology 2011;140:S842.
12. Fu XY. STAT3 in immune responses and inflammatory bowel diseases. Cell Res 2006;16:214-9.
13. Blackwell TS, Christman JW. The role of nuclear factor-κB in cytokine gene regulation. Am J Respir Cell Mol Biol 1997;17:3-9. (Pubitemid 127500814)
14. Bai AP, Hu PJ, Chen J, ChenW, PengW, Zeng Z, et al. Blockade of STAT3 by antisense oligonucleotide in TNBS-inducedmurine colitis. Int J Colorectal Dis 2007;22:625-35. (Pubitemid 47097033)
15. Mitsuyama K, Matsumoto S, Rose-John S, Suzuki A, Hara T, Tomiyasu N, et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 2006;55:1263-9. (Pubitemid 44277357)
16. DuvoixA,BlasiusR, DelhalleS, SchnekenburgerM,MorceauF,HenryE, et al.Chemopreventive and therapeutic effects of curcumin. Cancer Lett 2005;223:181-90. (Pubitemid 40719616)
17. Salh B, Assi K, Templeman V, Parhar K, Owen D, Gómez-Muñoz A, et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 2003;285:G235-43. (Pubitemid 36736407)
18. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005;11:2191-3. (Pubitemid 41504112)
19. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003;101:1053-62. (Pubitemid 36139379)
20. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995;270:24995-5000.
21. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immun 2003;171:3863-71. (Pubitemid 37254592)
22. Saydmohammed M, Joseph D, Syed V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J Cell Biochem 2010;110:447-56.
23. Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. British J Pharmacol 2003;139:209-18. (Pubitemid 36760353)
24. Ung VYL, Foshaug RR, MacFarlane SM, Churchill TA, Doyle JS, Sydora BC, et al. Oral administration of curcumin emulsified in carboxymethyl cellulose has a potent anti-inflammatory effect in the IL-10 gene-deficient mouse model of IBD. Dig Dis Sci 2010;55:1272-7.
25. Murthy SNS, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 1993;38:1722-34. (Pubitemid 23271431)
26. Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 1993;30(276):45443-55.
27. ten Hove T, van den Blink B, Pronk I, Pronk I, Drillenburg P, Peppelenbosch MP, et al. Dichotomal role of inhibition of p38MAPK with SB 203580 in experimental colitis. Gut 2002;50:507-12. (Pubitemid 34638870)
28. Natarajan C, Bright JJ. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through janus kinase-STAT pathway in T lymphocytes. J Immun 2002;169:6506-13. (Pubitemid 34620077)
29. KimYS, Ahn Y, HongMH, Joo SY, KimKH, Sohn IS, et al. Curcumin attenuates inflammatory responses of TNF-alpha-stimulated human endothelial cells. J Cardiovasc Pharmacol 2007;50:41-9. (Pubitemid 47220445)
30. Sugimoto K. Role of STAT3 in inflammatory bowel disease. World J Gastroenterol 2008;14:5110-4.
31. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001;193:483-96.
32. Kosiewicz MM, Nast CC, Krishnan A, Rivera-Nieves J, Moskaluk CA, Matsumoto S, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 2001;107:695-702. (Pubitemid 32225355)
33. Eaden JA, Abrams KR,Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35. (Pubitemid 32234798)
34. Munkholm P. Reviewarticle: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(Suppl. 2):1-5. (Pubitemid 37174709)
35. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
36. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009;457:200-4.
37. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-13.
38. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009;15:91-102.
39. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-900.
40. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998;64(4):353-6. (Pubitemid 28234275)